Subtype
Adult Central Nervous System Neoplasm
CI-CAN-00000416Explore in graph →
Non-malignant32 active trials1 evidence items
- NCIt
- C5131
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000416Explore in graph →
Clinical trials
204 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01148966 | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors | terminated | Phase 1 | 6 | University of WashingtonOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00085540 | FR901228 in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01920191 | Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma | completed | Phase 1 / Phase 2 | 19 | University Hospital, GenevaOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00085254 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | terminated | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00049387 | Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00979862 | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02227901 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT01407341 | Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer | terminated | Phase 1 | 1 | University of Southern CaliforniaOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00004262 | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00316849 | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00045565 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00006773 | Bortezomib in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2017source: clinicaltrials